Weekly Update: September 25th, 2023
As if there wasn’t enough uncertainty now were now in the middle of a huge auto workers strike and a potential government shutdown.
The Moody’s observation seems obvious, but what it really makes clear is that our government with its hyper-polarized environment has just about ground to halt in any case. Inflation is still on the rise and the economy is clearly sliding.
Do we need a full on recession before anyone wakes up.
Even though there are some bright spots in the markets with AI and so forth, conservative investors should continue to keep their powder dry and maybe write some covered calls against existing positions. Things are going to continue to go sideways for the foreseeable future.
Moody’s warns US government shutdown would be “credit negative”
NEW YORK, Sept 25 (Reuters) – A U.S. government shutdown would have negative implications for its credit assessment as it would highlight the weakness of U.S. institutional and governance strength compared to other top-rated governments, Moody’s said on Monday
U.S. government services would be disrupted and hundreds of thousands of federal workers furloughed without pay if Congress fails to provide funding for the fiscal year starting Oct. 1. The publication of major U.S. economic data of critical importance to policymakers and investors will also be suspended indefinitely should the federal government shut down.
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
9-8-23 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Announces Results of 2023 Annual Meeting
TORONTO, September 08, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:
|Director Nominee||Outcome||% For||% Withheld|
|Robert E. Hoffman||Elected||81.08%||18.92%|
Voting results on all matters voted on at the Meeting have been filed on SEDAR.
7-17-2023 International Food and Beverage (OTC IFBC)
Italian Food & Beverage Corp. Announces Strategic Partner
PLAINVIEW, NY-(Accesswire 07-17-2023) – Italian Food & Beverage Corp. (OTC- IFBC)
IFBC is now an approved vendor for Ferraro Foods, one of the country’s largest specialty distributors of food and foodservice supplies to Italian restaurants and pizzerias in the eastern U.S.
Ferraro Foods serves over 8,000 customers in 26 states. Recently they have announced a major expansion of its Long Island distribution business with the addition of a 230,000-square-foot warehouse, this distribution center is expected to increase capacity in the largest specialty Italian foods market.
IFBC is currently coordinating efforts with the Ferraro Foods New York distribution center in Melville, the mutual goal is to collaborate with each respective sales team to expand both companies’ reach to new clients while introducing the Dino Luzzi energy drink regular and sugar free to the existing ones.
The Dino Luzzi Energy Drink is the only energy drink made in Italy currently in the Ferraro Foods line, and is now distributed in the State of New York and its boroughs by Ferraro Foods.
It should be a perfect fit to bolster the company’s brand.
Dino Luzzi, CEO commented, “We are excited that Ferraro Foods is adding our brand to their clients.
This purchase order shows their trust in our product line. We are working with their sales team to increase sales while continuing marketing the product and, we will continue to do what is needed to increase shareholder value, looking forward to updating shareholders in the next few months.”
6-29/-23 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Year-End Results and Business Highlights
ompleted transition to otenaproxesul’s new formulation; tablet manufacturing underway
– PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024
– Ended year with $38.9 million in cash and equivalents
TORONTO, June 29, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2023.
“We made excellent progress in the year, much of it behind the scenes,” commented Dan Legault, Antibe’s CEO. “Foremost is the successful transition to otenaproxesul’s faster-absorbing formulation, a significant step that involved launching a new production process in a new plant. With comprehensive liver safety modeling in hand, we’re making final preparations for a short PK/PD study to finalize dose selection for the Phase II bunionectomy trial. We also completed candidate selection and a patent application filing for our IBD program and identified a new family of promising anti-inflammatory compounds. With our strong balance sheet, we’re poised to deliver shareholder value in the coming year.”
4-19-2023 Can B Corp. (OTC CANB)
Reports Growth of 45% to Company All-Time High $6.7 Million Annual Revenue
Led by Significant Increase in Duramed
Adjusted EBITDA Loss Decreased by 25% to $2.1 Million
HICKSVILLE, NY, April 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company’s financial results for the twelve months ended December 31, 2022.
Key Financial Highlights for 2022
- Revenue increased 45% to $6.7 million.
- Gross profit decreased 13% to $2.6 million.
- Gross margin decreased to 39.1%, due to a higher revenue percentage mix from Duramed.
- Adjusted EBITDA loss decreased by 25% to $2.1 million.
- Accounts receivable at $6.6 million.
- Inventory at $2.0 million.
- Total assets at $15.6 million.
- Total stockholders’ equity at $2.7 million.
Coeptis Therapeutics Holdings, Inc. NASDAQ (COEP)
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors
Clinical data from AML Clinical Trial Expected during 2H 2023
WEXFORD, Pa. , April 18, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.
3-15-2023 Can B Corp. (OTC CANB)
Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange
HICKSVILLE, NY, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products and durable medical devices, is pleased to announce it has successfully completed a corporate debt restructuring.
Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024. Specifically, three Promissory Notes issued to three funds in early 2022 and three Promissory Notes issued to three private investors in late 2022 were restructured to extend maturity dates to late in 2023 to give the Company an additional window to deploy the capital from the new raise.
3-6-2023 International Food and Beverage (OTC IFBC)
See the latest investor package. Dino is really getting traction.
Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama
Message me on Linkedin and check our latest commercial listings:
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
|9-25, 2023 COMPANY QUOTES, LISTINGS RESEARCH AND NEWS Coeptis Therapeutics, Inc. Ecrid, Inc (ECDD) Profile Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News Can B Corp (CANB) Profile News Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News International Food and Beverage Profile|
Screening for Timely and Liquid Stocks with Yield and EPS Growth
September 14, 2023 by Herb Blank
ValuEngine’s ratings from 1 (Strong Sell) to 5 (Strong Buy) are based upon our predictive model’s assessment of which stocks will appreciate most in price during the next 12 months on a percentage basis. As such, it will sometimes favor small stocks with a lower base for its highest ratings. Also, since it is price-appreciation focused, it does not take dividend income into account. Today, we use the ValuEngine Advanced Screening tool to select US stocks with at least $10 Billion market cap with predicted 12-month price appreciation of more than 5%, at least a 4 (Buy) rating, at least 2% dividend yield and at least 2% EPS growth. The goal is to select liquid stocks providing a better income yield than the S&P 500 Index and positive earnings growth of at least 2% in an economic environment where many pundits have said that most companies will struggle to deliver positive earnings growth.
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Black Swan Research Coverage and Subscription Service
Event Calendar Updates
The NIBA conference was a great success with a large number of attendees and a sold our presenters side.
Rocky Mountain Conference details available soon.
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update
SMM Global Twitter Acct (Impressions last 30 days) 520
Direct Email * 220,000